Takayasu arteritis: Takayasu arteritis (TAK) is a rare inflammatory large-vessel vasculitis primarily affecting the aorta and its major branches, but also other large vessels, causing stenosis, occlusion, or aneurysm.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
78 |
4. Check minimum number of eventsNone |
78 |
5. Include endpointsNone |
78 |
6. Filter based on genotype QC (FinnGen only) |
71 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M31
- Name in latin
- Syndroma arcus aortae
Similar endpoints
↥List of similar endpoints to
Aortic arch syndrome [Takayasu]
based on the number of shared cases.
Similar with more cases:
- Other necrotizing vasculopathies (FG)
- Other necrotizing vasculopathies
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 358 | 271 | 81 |
| Only index persons | 287 | 221 | 66 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 55.89 | 56.33 | 53.98 |
| Only index persons | 54.26 | 55.37 | 50.54 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 71 | 53 | 18 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 49.35 | 49.27 | 49.56 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 72
- Matched controls
- 720
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M31.4
ICD-10 Finland
Aortic arch syndrome [Takayasu]
+∞
100.6
71
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
23.7
43.4
46
50
L04AX03
ATC
methotrexate; systemic
19.6
37.8
42
48
H02AB06
ATC
prednisolone; systemic
15.8
19.7
64
242
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
11.1
18.6
24
31
L04AX01
ATC
azathioprine; systemic
50.6
16.3
19
5
M05BA04
ATC
alendronic acid; oral
20.5
15.4
23
16
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.3
14.7
52
189
R70.0
ICD-10 Finland
Elevated erythrocyte sedimentation rate
30.9
11.7
15
6
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
12.7
11.2
20
21
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.2
11.0
24
54
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.8
11.0
53
234
TPH04
NOMESCO Finland
Cathetrisation of vein
5.3
10.7
31
90
PAW37
NOMESCO Finland
Biopsy of temporal artery
+∞
10.7
10
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
5.7
10.5
25
61
M31.5
ICD-10 Finland
Giant cell arteritis with polymyalgia rheumatica
63.9
9.9
11
*
ZX120
NOMESCO Finland
Intravenous
6.0
9.8
21
46
M31.6
ICD-10 Finland
Other giant cell arteritis
114.4
9.7
10
*
4467A
ICD-9 Finland
Polyarteritis nodosa and allied conditions, Takayasu's disease
+∞
9.6
9
*
I77.6
ICD-10 Finland
Arteritis, unspecified
+∞
9.6
9
*
PD5CG
NOMESCO Finland
Extensive MRI examination of thoracal and abdominal aortta with high intensity magnet
+∞
9.6
9
*
PD5AD
NOMESCO Finland
CT of aorta
101.4
8.6
9
*
PD5DG
NOMESCO Finland
Very extensive MRI examination of thoracal and abdominal aortta with high intensity magnet
+∞
8.5
8
*
M35.3
ICD-10 Finland
Polymyalgia rheumatica
17.7
8.0
12
8
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
8.2
7.7
17
26
L04AA06
ATC
mycophenolic acid; systemic
88.9
7.6
8
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.4
7.4
17
39
M34.1
ICD-10 Finland
CR(E)ST syndrome
+∞
7.4
7
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
10.3
6.9
13
15
H02AB07
ATC
prednisone; oral
4.6
6.4
18
49
PD5BD
NOMESCO Finland
Extensive CT of aorta
29.5
6.4
8
*
4AC07, ,
NOMESCO Finland
+∞
6.3
6
*
M31.9
ICD-10 Finland
Necrotizing vasculopathy, unspecified
+∞
6.3
6
*
M05BA07
ATC
risedronic acid; oral
14.2
6.3
10
8
L88
ICPC
Rheumatoid/seropositive arthritis
9.3
6.1
12
15
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
8.1
6.1
13
19
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
7.3
6.1
14
23
A02BC02
ATC
pantoprazole; systemic
4.7
6.0
61
388
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
62
318
7.84
10.59
9.9
8.4
1.21
1.22
mmol/l
0.97
53
270
63
362
6.91
9.58
4.9
3.4
0.00
0.00
estimate
-0.00
11
77
63
368
6.68
9.21
4.9
3.4
100.50
0.00
estimate
0.47
12
79
63
372
6.54
8.87
5.0
3.5
0.00
0.00
estimate
-0.00
11
73
15
17
10.81
8.02
1.7
1.1
1.20
1.21
g/l
0.02
15
17
15
17
10.81
8.02
1.7
1.1
0.22
0.24
g/l
0.47
15
17
20
61
4.16
6.13
3.3
2.2
463.35
387.71
nmol/l
0.21
20
56
11
15
8.43
5.37
1.2
1.2
—
—
—
0
0
8
6
14.76
5.21
1.3
1.0
—
—
—
0
0
10
13
8.72
5.04
1.0
1.2
—
—
—
0
0
24
96
3.25
4.85
4.7
2.6
0.53
0.98
e6/l
0.83
15
46
10
15
7.54
4.65
1.0
1.5
—
—
—
0
0
8
9
9.81
4.40
1.1
1.4
—
—
—
0
0
34
174
2.81
4.38
5.8
2.7
0.97
0.35
e6/l
0.36
27
123
9
13
7.73
4.31
1.8
1.2
0.00
0.00
g/l
—
9
13
39
219
2.70
4.14
6.1
2.6
—
—
—
0
0
22
91
3.04
4.14
5.0
2.7
2.15
3.99
e6/l
0.41
13
41
9
14
7.17
4.12
1.8
1.1
0.11
0.00
g/l
—
9
14
9
14
7.17
4.12
1.0
1.4
—
—
—
0
0
9
15
6.68
3.95
1.1
1.5
—
—
—
0
0
18
69
3.14
3.82
11.8
8.4
103.06
103.81
mmol/l
0.20
18
69
44
270
2.62
3.80
6.8
5.2
33.45
35.64
g/l
1.43
44
258
39
226
2.58
3.80
4.8
3.1
30.38
27.57
u/l
0.41
39
215
9
16
6.26
3.79
1.0
1.5
—
—
—
0
0
24
109
2.80
3.79
3.0
3.3
0.82
0.81
mmol/l
0.33
24
101
8
12
7.34
3.78
1.9
1.2
0.00
0.00
g/l
—
8
12
18
70
3.10
3.73
2.2
1.6
—
—
—
0
0
18
70
3.10
3.73
2.1
1.6
—
—
—
0
0
7
9
8.46
3.64
1.0
1.8
—
—
—
0
0
27
138
2.53
3.33
1.4
1.3
42.30
8.92
u/ml
0.55
11
60
6
7
9.21
3.33
1.2
1.0
—
—
—
0
0
6
7
9.21
3.33
1.2
1.0
—
—
—
0
0
24
116
2.60
3.32
7.2
4.1
87.18
116.65
ng/l
0.13
17
82
7
11
6.91
3.27
1.1
1.3
—
—
—
0
0
9
20
4.98
3.23
1.4
1.4
—
—
—
0
0
6
8
8.05
3.11
1.0
1.8
—
—
—
0
0
21
100
2.55
2.96
2.4
1.7
—
—
—
0
0
12
39
3.48
2.94
2.8
1.5
—
—
—
0
0
7
14
5.41
2.80
1.0
1.4
—
—
—
0
0
13
49
3.02
2.80
4.8
4.3
83.12
67.75
ng/l
0.31
13
42
5
6
8.83
2.79
1.0
2.0
—
—
—
0
0
43
287
2.24
2.76
4.3
3.2
0.00
0.00
estimate
—
9
64
6
10
6.42
2.75
1.0
1.6
—
—
—
0
0
5
7
7.56
2.59
1.0
1.3
—
—
—
0
0
26
147
2.20
2.46
1.5
1.3
19.81
44.55
iu/ml
—
9
48
5
8
6.61
2.41
1.0
1.8
—
—
—
0
0
0
62
0.00
2.36
0.0
2.2
—
—
—
0
0
9
29
3.40
2.32
15.1
6.1
25.16
24.67
mmol/l
—
9
29
7
18
4.19
2.31
3.4
2.4
—
—
—
0
0
7
18
4.19
2.31
1.6
1.3
—
—
—
0
0
28
169
2.07
2.21
5.2
3.0
1.02
1.02
kg/l
0.01
22
108
0
55
0.00
2.18
0.0
2.2
—
—
—
0
0
13
57
2.56
2.12
3.8
4.2
2.32
2.04
mmol/l
0.10
13
48
7
20
3.76
2.11
1.3
1.3
—
—
—
0
0
8
28
3.08
1.93
18.0
12.0
0.68
0.77
%
—
8
28
32
212
1.92
1.90
4.7
3.2
0.00
0.00
estimate
—
10
68
6
17
3.75
1.88
1.3
1.5
—
—
—
0
0
8
29
2.97
1.85
18.0
11.8
1.79
1.76
%
—
8
29
5
12
4.39
1.85
1.6
1.2
—
—
—
0
0
6
18
3.54
1.78
1.0
1.5
—
—
—
0
0
7
24
3.12
1.77
3.6
1.5
89.14
96.67
%
—
7
24
25
156
1.92
1.75
2.6
1.7
0.69
1.04
mg/l
0.72
19
123
12
59
2.24
1.54
2.2
3.2
22.58
28.40
u/l
0.93
12
47
7
29
2.56
1.43
1.1
1.3
—
—
—
0
0
34
246
1.72
1.43
5.0
3.0
175.42
35.48
ng/l
0.52
21
156
6
23
2.75
1.40
4.0
2.0
172.50
202.78
%
—
6
23
30
211
1.72
1.38
3.3
2.9
0.00
0.00
estimate
—
10
59
38
287
1.69
1.34
2.2
1.9
1.37
1.43
mmol/l
0.14
33
243
8
35
2.44
1.32
3.9
3.9
24.88
24.59
mmol/l
—
8
35
24
161
1.74
1.29
2.5
2.1
—
—
—
0
0
36
272
1.65
1.24
2.5
2.0
103.24
102.78
pmol/l
0.01
22
135
7
34
2.17
1.06
1.6
1.7
—
—
—
0
0
41
331
1.55
1.01
3.2
2.8
—
—
estimate
—
0
0
0
28
0.00
1.00
0.0
1.5
—
276.33
—
0
15
6
27
2.33
0.96
21.7
11.2
24.83
24.35
mmol/l
—
6
27
17
114
1.64
0.90
2.0
2.9
2.49
2.46
mmol/l
0.66
17
107
27
204
1.52
0.87
4.2
3.8
8.39
7.73
mg/mmol
0.06
18
120
6
32
1.95
0.84
1.7
1.6
—
—
—
0
0
19
136
1.54
0.77
1.5
1.7
—
—
—
0
0
7
43
1.69
0.69
1.6
1.4
38.93
25.10
iu/l
—
7
38
57
514
1.52
0.69
5.4
4.8
14.65
14.76
pmol/l
0.15
57
477
64
599
1.62
0.61
6.7
5.8
1.92
1.81
mu/l
0.30
64
563
5
88
0.54
0.61
5.2
4.9
36.80
33.12
%
—
5
58
0
22
0.00
0.60
0.0
2.1
—
—
—
0
0
59
545
1.46
0.53
49.2
18.4
327.27
332.18
g/l
3.82
59
545
7
48
1.51
0.48
1.6
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
2.1
—
—
—
0
0
9
65
1.44
0.41
4.4
3.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
5
79
0.61
0.38
1.0
2.0
2.72
3.32
ratio
—
5
62
10
77
1.35
0.28
6.0
4.0
24.48
20.30
%
—
5
35
49
458
1.22
0.27
5.4
3.2
60.18
44.75
u/l
0.88
44
444
42
449
0.84
0.23
4.1
3.5
—
—
—
0
0
5
39
1.30
0.23
4.2
2.5
1.16
1.40
%
—
5
39
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
51.37
—
0
10
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
11
128
0.83
0.15
1.9
1.4
—
—
—
0
0
5
43
1.17
0.10
6.8
3.2
4.76
4.34
pmol/l
—
5
38
5
45
1.12
0.10
1.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.9
—
62.00
—
0
7
0
8
0.00
-0.00
0.0
1.1
—
14.69
—
0
8
7
71
0.98
-0.00
10.3
5.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
11.59
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_TAKAYASU and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have M13_TAKAYASU.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: M13_TAKAYASU – Aortic arch syndrome [Takayasu]
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data